Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 11:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 112 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Motor Vehicle Accident Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Mobile Technology Monitoring System to Assess a Web-based Intervention for Teen Risky Driving

NCT02695888
View directory record Official record
Conditions
Adolescent, Accidents, Traffic, Attention, Motor Vehicles
Interventions
Risky Driving Prevention, Teen Healthy Living
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
16 Years to 17 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Jun 10, 2026, 11:56 AM EDT
Recruiting Phase 1 Interventional

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma

NCT05432635
View directory record Official record
Conditions
B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Transformed Non-Hodgkin Lymphoma
Interventions
Anti-CD19-CAR CMV-specific T-lymphocytes, Autologous Hematopoietic Stem Cell Transplantation, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine, Myeloablative Conditioning
Biological · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Jun 10, 2026, 11:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers

NCT02743455
View directory record Official record
Conditions
Yellow Fever, Yellow Fever Immunisation
Interventions
ISA-720, MVA Smallpox Vaccine, MVA-BN Yellow Fever Vaccine, Placebo, YF Vax 17D Strain
Drug · Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Iowa City, Iowa • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Jun 10, 2026, 11:56 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox

NCT05740982
View directory record Official record
Conditions
Monkeypox
Interventions
JYNNEOS
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 50 Years
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
17
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jun 10, 2026, 11:56 AM EDT
Terminated Phase 2 Interventional Results available

A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI

NCT03236311
View directory record Official record
Conditions
Microvascular Coronary Artery Disease
Interventions
SAR407899, Placebo, Adenosine, Regadenoson, 13N-ammonia, 82Rubidium
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Los Angeles, California • Jacksonville, Florida • Wellington, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Jun 10, 2026, 11:56 AM EDT
Completed Not applicable Interventional

Effects of Antagonistic Actions in Response to Trauma Exposure

NCT04617769
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Psychoeducation, Exposure
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 60 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Jun 10, 2026, 11:56 AM EDT
Withdrawn Phase 2 Interventional

Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

NCT03438344
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Bone Marrow Transplantation Recipient, Chronic Lymphocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic Cell Transplantation Recipient, Hodgkin Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma
Interventions
Multi-antigen CMV-Modified Vaccinia Ankara Vaccine, Laboratory Biomarker Analysis, Placebo
Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
Duarte, California • Atlanta, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Jun 10, 2026, 11:56 AM EDT
Recruiting Phase 1 Interventional

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma

NCT05801913
View directory record Official record
Conditions
High Grade B-Cell Non-Hodgkin's Lymphoma, Intermediate Grade B-Cell Non-Hodgkin's Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
Interventions
Anti-CD19-CAR CMV-specific T-lymphocytes, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Leukapheresis, Lymphodepletion Therapy, Magnetic Resonance Imaging, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine, Positron Emission Tomography, X-Ray Imaging
Biological · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Jun 10, 2026, 11:56 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention

NCT02315703
View directory record Official record
Conditions
Healthy
Interventions
Ad26.Mos.HIV, MVA-Mosaic, gp140 DP Low-dose, gp140 DP High-dose, Placebo
Biological · Drug
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
393 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2022
U.S. locations
5
States / cities
Aurora, Colorado • Miami, Florida • Rockville, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Jun 10, 2026, 11:56 AM EDT
Recruiting Phase 1Phase 2 Interventional

Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant

NCT03354728
View directory record Official record
Conditions
Cytomegaloviral Infection, Hematopoietic Cell Transplant Recipient
Interventions
Laboratory Biomarker Analysis, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
Other · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
1 Year to 21 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Jun 10, 2026, 11:56 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation

NCT04060277
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm, Hodgkin Lymphoma, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma
Interventions
Letermovir, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine, Placebo Administration
Drug · Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Jun 10, 2026, 11:56 AM EDT
Completed Phase 2 Interventional Results available

Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection

NCT02038881
View directory record Official record
Conditions
Smallpox
Interventions
IMVAMUNE®
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 45 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Jun 10, 2026, 11:56 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Evaluating the Human Immune Response to the JYNNEOS Vaccine

NCT06366672
View directory record Official record
Conditions
Vaccinia, Virus Diseases
Interventions
JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) suspension for subcutaneous injection, Phlebotomy, Research bronchoscopy, Skin punch biopsy, Bone marrow aspiration
Biological · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Jun 10, 2026, 11:56 AM EDT
Completed Not applicable Interventional

Examining Written Disclosure as a Treatment for Post-Traumatic Stress Disorder

NCT00862498
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
Written Disclosure
Other
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Jun 10, 2026, 11:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Web-based Intervention to Prevent Risky Driving

NCT02319317
View directory record Official record
Conditions
Adolescent, Accidents, Traffic, Attention, Motor Vehicles
Interventions
Risky driving prevention, Control group general health promotion
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
16 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Jun 10, 2026, 11:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to an HIV Vaccine Boost Following the Administration of Two HIV Vaccines, in HIV-Uninfected, Healthy Adults (Study Extension to HVTN 073/SAAVI 102)

NCT01423825
View directory record Official record
Conditions
HIV Infections
Interventions
Sub C gp140 Vaccine, MF59C.1 Adjuvant, Sodium chloride
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Jun 10, 2026, 11:56 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers Results available

CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant

NCT03560752
View directory record Official record
Conditions
Accelerated Phase CML, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Chronic Lymphocytic Leukemia, Chronic Phase CML, BCR-ABL1 Positive, Cytomegalovirus Positive, Donor, Hematopoietic Cell Transplant Recipient, Hodgkin Lymphoma, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Myelofibrosis, Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Jun 10, 2026, 11:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Trial of Smallpox Vaccine

NCT00046397
View directory record Official record
Conditions
Healthy
Interventions
Modified Vaccinia Virus Ankara TBC-M
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
195 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 10, 2026, 11:56 AM EDT
Recruiting Early Phase 1 Interventional

Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia

NCT06735690
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Anti-CD19-CAR CMV-specific T-lymphocytes, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Echocardiography, Leukapheresis, Lumbar Puncture, Magnetic Resonance Imaging, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine, Multigated Acquisition Scan, Positron Emission Tomography, Transplant Conditioning, X-Ray Imaging
Procedure · Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Jun 10, 2026, 11:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205

NCT02852005
View directory record Official record
Conditions
HIV Infections
Interventions
MVA/HIV62B vaccine, AIDSVAX B/E vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2022 · Synced Jun 10, 2026, 11:56 AM EDT
Completed Phase 1 Interventional

A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine in HIV-1 Infected Adults on ART

NCT01378156
View directory record Official record
Conditions
HIV-1 Infection
Interventions
JS7 plasmid DNA and MVA62B vaccine
Biological
Lead sponsor
GeoVax, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Birmingham, Alabama • Los Angeles, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Jun 10, 2026, 11:56 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

CS DNA MVA Trial in Mampong, Ghana

NCT00377494
View directory record Official record
Conditions
Plasmodium Falciparum Malaria
Interventions
MVA-CSO Vaccine, PfCSP DNA (VCL-2510) Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2008
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Jun 10, 2026, 11:56 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Vitamin D to ENhance TraUma REcovery

NCT05458024
View directory record Official record
Conditions
Musculoskeletal Pain
Interventions
Vitamin D 2, Vitamin D2 Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
4
States / cities
Worcester, Massachusetts • St Louis, Missouri • Camden, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Jun 10, 2026, 11:56 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD)

NCT00389103
View directory record Official record
Conditions
Smallpox, Atopic Dermatitis
Interventions
MVA (smallpox vaccine)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 35 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
3
States / cities
Albuquerque, New Mexico • Portland, Oregon • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2014 · Synced Jun 10, 2026, 11:56 AM EDT